Association between VEGF expression in tumour-associated macrophages and elevated serum VEGF levels in primary colorectal cancer patients

2007 ◽  
Vol 3 (6) ◽  
pp. 325-333 ◽  
Author(s):  
Francisco J. Gonzalez ◽  
Luis Vicioso ◽  
Martina Alvarez ◽  
Isabel Sevilla ◽  
Eduardo Marques ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Elevated Serum ◽  
Primary Colorectal Cancer ◽  
Vegf Expression ◽  
Colorectal Cancer Patients

Preoperative Vascular Endothelial Growth Factor Levels as a Prognostic Marker for Stage II or III Colorectal Cancer Patients

2011 ◽  
Vol 4 ◽  
pp. CGM.S7113 ◽  
Author(s):  
Ozgur Kemik ◽  
Ahu Sarbay Kemik ◽  
Aziz Sümer ◽  
Sevim Purisa ◽  
A. Cumhur Dulger ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Patients ◽  
Elevated Serum ◽  
Stage Ii ◽  
Vascular Endothelial ◽  
Poor Survival ◽  
Colorectal Cancer Patients ◽  
Endothelial Growth Factor

Background The aim of the present study was to determine whether serum vascular endothelial growth factor (VEGF) can provide prognostic information independent of carcinoembryonic antigen levels in patients undergoing curative surgery. Methods Serum samples were collected from 158 patients with colorectal cancer and from 100 controls. Serum and tissue levels of VEGF were measured by enzyme-linked immunosorbent assay. Serum VEGF levels in colorectal cancer patients were compared with those in healthy controls, and we retrospectively assessed the association between serum VEGF levels and clinicopathologic findings and survival. Results VEGF expression was significantly higher in colorectal cancer tissue compared with nontumor tissue. Mean serum VEGF levels in patients were significantly higher than those in controls, and significantly higher in patients with large tumors, lymph node involvement, and distant metastases. Conclusion Elevated serum VEGF was significantly associated with poor survival, but was only an independent risk factor for poor survival in Stage II and/or III disease. Elevated serum VEGF is significantly associated with development of colorectal cancer, and lymph or distant invasive phenotypes and survival, especially in Stage II and III patients.

Elevated serum VEGF levels in colorectal cancer patients correlate with poor survival

2001 ◽  
Vol 37 ◽  
pp. S304 ◽  
Author(s):  
A. Karayiannakis ◽  
K. Syrigos ◽  
A. Zbar ◽  
N. Baibas ◽  
D. Tsioulos ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Elevated Serum ◽  
Poor Survival ◽  
Colorectal Cancer Patients

Expression of EGFR, VEGF, and K-ras mutation as predictors for response of cetuximab in colorectal cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15147-e15147
Author(s):  
D. Hwang ◽  
E. Jung ◽  
S. Cho
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Direct Sequencing ◽  
Expression Level ◽  
Vegf Expression ◽  
Ras Mutation ◽  
Mutation Status ◽  
Downstream Signaling ◽  
Egfr Expression ◽  
Colorectal Cancer Patients

e15147 Background: Cetuximab has been effective in metastatic colorectal cancer (CRC) patients. EGFR is involved in CRC through its downstream signaling pathways, including RAS and MAKP pathway and angiogenesis. We evaluated the predictive value of EGFR and VEGF expressions and K-ras mutation status in colorectal cancer patients treated with cetuximab in combination with chemotherapy Methods: Our study included 29 CRC patients treated with cetuximab in combination with chemotherapy (20 patients with FOLFIRI and 5 patients with FOLFOX, and 4 patients with monotherapy). Paraffin blocked tumor tissues were analyzed for EGFR and VEGF expression using quantitative real time PCR and K-ras mutation status (codons 12 and 13) using direct sequencing. Results: 12 patients (43%) had a partial response (PR) and 6 patients (21%) with stable disease (SD) and 11 patients (38%) with progressive disease (PD). EGFR expression was not correlated with the response of cetuximab (p=0.60) The median EGFR expression level was 0.30 x 10-3 in PR and 0.25 x 10-3 in SD and 0.26 x 10-3 in PD. High VEGF expression was associated with the response of cetuximab (p=0.03). The mean VEGF expression level was 4.3 x 10-3 in PR and 1.64 x 10-3 in SD and 1.72 x 10-3 in PD. A K-ras mutation was present in 45 % (13/29) and did not significantly correlated with non-response of cetuximab (p=0.05). A K-ras mutation was detected 33% (4/12) in PR and 33% (2/6) in SD and 70 % (7/10) in PD. Conclusions: VEGF expression in tumor may be a potential predictor for the response of cetuximab. But EGFR expression and K-ras mutation status is not significantly correlated with clinical outcome of cetuximab. And a K-ras mutation is found in the response group. [Table: see text]

Patterns of serum CEA levels in different clinico-pathological variables of colorectal cancer

2020 ◽  
Vol 14 (2) ◽  
pp. 68-71
Author(s):  
Muhammad Hayat ◽  
Ghulam Haider ◽  
Shahid Hussain ◽  
Perwasha Kerio ◽  
Ravisha Bai ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Tertiary Care ◽  
Elevated Serum ◽  
Response To Therapy ◽  
Care Hospital ◽  
Significant Difference ◽  
Serum Carcinoembryonic Antigen ◽  
Serum Cea ◽  
Colorectal Cancer Patients

Background: Globally, colorectal malignancy is the 3rd most frequent cancer and the 2nd major cause of mortality. Serum carcinoembryonic antigen (CEA) is a simple tumor marker for the diagnosis, predicting response to therapy and survival and identifying the recurrence of colorectal cancer. Therefore, the aim was to evaluate the pattern of serum CEA levels in patients with colorectal cancer presenting at a tertiary care hospital in Karachi Patients and methods: It was a cross-sectional study conducted at the Department of Medical Oncology of Jinnah Postgraduate Medical Center, Karachi from January till August 2019. One ninety-nine patients of 12-80 years age and either gender diagnosed with colorectal cancer (biopsy-proven) were included. Data on demographics, clinical and pathological findings were recorded in the pre-designed proforma. The serum CEA levels in colorectal cancer patients were assessed using an ELISA kit. CEA levels higher than 5.0 ng/mL were deemed as elevated CEA levels in colorectal patients. Data were analyzed using SPSS version 23. Results: A total of 191 colorectal cancer patients were included. The mean age of the patients was 42.81±15.22 years. Most of the patients (61.3%) were male. Out of 191 colorectal cancer patients, 60 (31.4%) had CEA level 0-0.3 ng/ml, whereas 79 (41.4%) had elevated serum CEA level (>10 ng/ml). The CEA levels were stratified with respect to effect modifiers. The size of the tumor, TNM staging and localization and metastasis of cancer showed a statistically significant difference between levels of CEA (p<0.05). Conclusion: The raised CEA levels are associated with clinically progressive or presence of residual and recurrent disease. For patients with progressive tumors, particularly colorectal carcinoma, CEA assays are an important guide to assess the burden of the tumor, hence clinicians and surgeons ought to monitor antigen levels. It is recommended to enhance the clinical efficacy of the CEA levels.

scholarly journals Effect of FOLFOX6 chemotherapy on serum VEGF expression in advanced colorectal cancer patients

2019 ◽  
Vol 65 (2) ◽  
pp. 177-182
Author(s):  
Kong Ying ◽  
Yang Chong ◽  
Wang Wei ◽  
Dong Bing ◽  
Su Yanyan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Advanced Colorectal Cancer ◽  
Total Efficiency ◽  
Therapeutic Effects ◽  
Vascular Endothelial ◽  
Vegf Expression ◽  
Before And After ◽  
Colorectal Cancer Patients ◽  
Endothelial Growth Factor

SUMMARY OBJECTIVE: To explore the effect of FOLFOX6 chemotherapy on serum vascular endothelial growth factor (VEGF) expression in advanced colorectal cancer patients. METHODS: A retrospective analysis of 81 patients with advanced colorectal cancer who visited our hospital from March 2014 to February 2016 was performed. All the patients were treated with FOLFOX6 chemotherapy. On day 1, patients received oxaliplatin 100 mg/m2 ivgtt (2h), calcium folinate 200 mg/m2 ivgtt (2h), 5 fluorouracil 400 mg/m2 iv bolus and 5 fluorouracil 2500 mg/m2 ivgtt (5h). The treatment course was 2 weeks, and 4 treatment courses were required. The changes in the levels of VEGF and CRP and quality of life before and after 4 courses of chemotherapy were observed and therapeutic effects and adverse reactions after chemotherapy were evaluated. RESULTS: After treatment, the total efficiency of chemotherapy was 82.72% (67/81) with 24 cases in complete remission, 25 cases in partial response, 18 cases in stable disease and 14 cases in progressive disease. The levels of CRP and VEGF after the treatment were significantly lower than those before treatment (5.69±0.77) mg/L vs. (7.99±1.36) mg/L; (443.26±21.55) pg/mL vs. (542.83±20.44) pg/mL] (P<0.05). The KPS grade after treatment was significantly higher than that before treatment (57.84±4.6) point vs. (50.99±3.73) point] (P<0.05). Among them, 3 cases developed a rash, 5 cases experienced hair loss, and 9 cases developed nausea and vomiting. CONCLUSION: FOLFOX6 chemotherapy can decrease serum VEGF expression in patients with advanced colorectal cancer and enhance the curative effect with high safety, which is good for the improvement of patients' survival.

Sign in / Sign up

Export Citation Format

Share Document